fulvestrant has been researched along with molsidomine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandross, KJ; Flint, N; Lee, L; Merrill, J; Takao, T; Ying, X | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for fulvestrant and molsidomine
| Article | Year |
|---|---|
17beta-estradiol protects oligodendrocytes from cytotoxicity induced cell death.
Topics: Animals; Cell Compartmentation; Cell Death; Cell Division; Cell Nucleus; Cells, Cultured; Cytoprotection; Cytosol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; L-Lactate Dehydrogenase; Male; Molsidomine; Nitric Oxide Donors; Oligodendroglia; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; RNA, Messenger | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |